罗格列酮对乙烯雌酚诱发的大鼠泌乳素腺瘤治疗作用的初步研究  

Effect of rosiglitazone on diethylstilbestrol-induced rat prolactinoma

作　　者：戴克[1] 王守森[1] 王如密[1] 魏梁锋[1] 陈富勇[1] 

机构地区：[1]中国人民解放军南京军区福州总医院神经外科,福建福州350025

出　　处：《中国微侵袭神经外科杂志》2006年第10期454-458,共5页Chinese Journal of Minimally Invasive Neurosurgery

摘　　要：目的采用乙烯雌酚(DES)诱发方法建立垂体催乳素(PRL)腺瘤模型,研究罗格列酮对PRL腺瘤的影响。方法首先将20只雌性Wistar大鼠分为皮下植入含DES硅胶管的DES组(A0组)及皮下植入空白硅胶管的空白对照组(B0组)。8周后处死所有大鼠,观察并比较两组大鼠的血清PRL水平、垂体质量、垂体中PRL蛋白分布及细胞周期素D1(Cyclin D1)的表达。然后取雌性Wistar大鼠40只,皮下均植入含DES的硅胶管,8周时分为空白对照组(A组),溴隐亭组(B组)、大剂量罗格列酮组(C组)、中剂量罗格列酮组(D组)、小剂量罗格列酮组(E组)。药物干预4周后分别处死大鼠,观察各组大鼠血清PRL水平、垂体质量、垂体中PRL蛋白分布及Cyclin D1的表达。结果雌性Wistar大鼠皮下埋植含DES的硅胶管8周后均能形成垂体PRL腺瘤。在B、C组,药物干预后血清PRL值、垂体质量、垂体中PRL蛋白分布均较A、D、E、A0组降低,差异有统计学意义(P<0.05);但B、C组间差异无统计学意义(P>0.05)。C组垂体中Cyclin D1表达较A、B组及A0组降低,差异有统计学意义(P<0.05)。结论罗格列酮对DES诱发的大鼠PRL腺瘤有治疗作用。Objective To establish a prolactinoma model induced by diethylstilbestrol （DES） in female Wistar rats, and study the effects of rosiglitazone on rat prolactinoma. Methods Firstly, twenty female Wistar rats were divided into 2 groups at random. Each rat in DES group （A0） was subcutaneously implanted with DES encapsulated in silastic tube. Each rat in control group （B0） was implanted with blank silastic tube. After 8 weeks, all the animals were sacrificed for weight of the pituitary gland, serum prolactin （PRL） level, PRL-immunoreactive cell count and cyclin D1 expression in prolactinoma. Secondly, forty female Wistar rats were subcutaneously implanted with DES encapsulated in silastic tube. After 8 weeks, rats in DES group were divided into control group （A）, bromocriptine group （B）, high dose rosiglitazone group （C）, middle dose rosiglitazone group （D）, and low dose rosiglitazone group （E）. After 4 weeks of treatment, all the animals were sacrificed for weight of the pituitary gland, serum PRL level, PRL-immunoreactive cell count and cyclin D1 expression in prolactinoma. Results Subcutaneous DES implantation is capable of forming prolactinoma in female Wistar rats. After 8 weeks, the serum PRL levels, weight of pituitary gland, PRL-immunoreactive cell count in groups B and C were significantly lower than those in groups A, D, E or A0 （P〈0.05）. All the parameters showed no difference between group B and C （P〉0.05）. The expression of cyclin D1 in group C was significantly lower than those of groups A, B or A0 （P〈0.05）. Conclusion Rosiglitazone has therapeutic effect against DES-induced prolactinoma in rats.

关 键 词：罗格列酮 乙底酚 大鼠 WISTAR 催乳素瘤 治疗 

分 类 号：R736.4[医药卫生—肿瘤]